小分子多肽免疫抑制剂PET探针引导肿瘤免疫治疗新进展

doi:10.3760/cma.j.issn.1673-422X.2019.08.001

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (8): 449-452.doi: 10.3760/cma.j.issn.1673-422X.2019.08.001

• 卫生健康事业发展70年巡礼 • 下一篇

小分子多肽免疫抑制剂PET探针引导肿瘤免疫治疗新进展

蒋金泉,刘特立,夏雷,朱华,杨志

北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科恶性肿瘤发病机制及转化研究教育部重点实验室 100142

收稿日期:2019-03-05 修回日期:2019-03-24 出版日期:2019-08-08 发布日期:2019-10-31
通讯作者: 朱华 E-mail:zhuhuananjing@163.com
基金资助:
国家自然科学基金（81401467、81671733）

PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy

Jiang Jinquan, Liu Teli, Xia Lei, Zhu Hua, Yang Zhi

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education); Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China

Received:2019-03-05 Revised:2019-03-24 Online:2019-08-08 Published:2019-10-31
Contact: Zhu Hua E-mail:zhuhuananjing@163.com
Supported by:
National Natural Science Foundation of China (81401467, 81671733)

摘要/Abstract

摘要： 靶向程序性死亡蛋白-1及其配体（PD-1/PD-L1）的免疫抑制剂是目前实体肿瘤免疫治疗的研究热点。通过分子影像方法检测实体肿瘤患者体内PD-1/PD-L1表达情况能够预测肿瘤患者能否从免疫治疗中获益。小分子多肽抑制剂具有相对分子质量低、在肿瘤微环境中扩散速度快、分布均匀、容易到达实体肿瘤深部等显著优势。通过放射性核素标记小分子多肽抑制剂的分子探针PET显像，能够非侵入性、实时、定量地检测肿瘤患者体内PD-1/PD-L1表达，有望为患者筛选、疗效监测、治疗方案优化、预后评估提供新的检测手段。

关键词: 免疫抑制剂, 正电子发射断层显像术, 免疫疗法

Abstract: Immunosuppressant targeting programmed death protein-1 and its ligand (PD-1/PD-L1) is a hot topic in solid tumor immunotherapy. Detection of PD-1/PD-L1 expression in solid tumor patients by molecular imaging can predict whether tumor patients can benefit from immunotherapy. Small molecular polypeptide inhibitors have the advantages of low molecular weight, fast diffusion in tumor microenvironment, uniform distribution and easy access to the deep part of solid tumor. Non-invasive, real-time and quantitative detection of PD-1/PD-L1 expression in tumor patients can be performed by radionuclide labeled small molecular polypeptide inhibitor molecular probe PET imaging. It is expected to provide new detection methods for patient screening, efficacy monitoring, treatment plan optimization and prognosis evaluation.

Key words: Immunosuppressive agents, Positron-emission tomography, Immunotherapy

蒋金泉, 刘特立, 夏雷, 朱华, 杨志. 小分子多肽免疫抑制剂PET探针引导肿瘤免疫治疗新进展[J]. 国际肿瘤学杂志, 2019, 46(8): 449-452.

Jiang Jinquan, Liu Teli, Xia Lei, Zhu Hua, Yang Zhi. PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy[J]. Journal of International Oncology, 2019, 46(8): 449-452.

参考文献

［1］ Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer［J］. Nat Rev Clin Oncol, 2014, 11(1): 24-37. DOI: 10.1038/nrclinonc.2013.208. ［2］ Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1positive advanced gastric cancer (keynote-012): a multicentre, open-label, phase 1b trial［J］. Lancet Oncol, 2016, 17(6): 717-726. DOI: 10.1016/S1470-2045(16)00175-3. ［3］ Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ono-4538-12, attraction-2): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 390(10111): 2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. ［4］ Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematicreview and meta-analysis［J］. Crit Rev Oncol Hematol, 2016, 100: 88-98. DOI: 10.1016/j.critrevonc.2016.02.001. ［5］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［6］ Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］. Clin Cancer Res, 2014, 20(19): 5064-5074. DOI: 10.1158/1078-0432.CCR-13-3271. ［7］ Chatterjee S, Lesniak WG, Gabrielson M, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors［J］. Oncotarget, 2016, 7(9): 10215-10227. DOI: 10.18632/oncotarget.7143. ［8］ Natarajan A, Mayer AT, Reeves RE, et al. Development of novel immunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model［J］. Mol Imaging Biol, 2017, 19(6): 903-914. DOI: 10.1007/s11307-017-1060-3. ［9］ Hettich M, Braun F, Bartholoma MD, et al. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers［J］. Theranostics, 2016, 6(10): 1629-1640. DOI: 10.7150/thno.15253. ［10］ Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer［J］. Lab Invest, 2014, 94(1): 107-116. DOI: 10.1038/labinvest.2013.130. ［11］ Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells［J］. PLoS One, 2014, 9(2): e88557. DOI: 10.1371/journal.pone.0088557. ［12］ Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway［J］. N Engl J Med, 2016, 375(18): 1767-1778. DOI: 10.1056/NEJMra1514296. ［13］ Shukuya T, Mori K, Amann JM, et al. Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies［J］. J Thorac Oncol, 2016, 11(11): 1927-1939. DOI: 10.1016/j.jtho.2016.07.017. ［14］ Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and nsclc［J］. Cancer Immunol Res, 2017, 5(5): 417-424. DOI: 10.1158/2326-6066.CIR-16-0325. ［15］ Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma［J］. Blood, 2017, 130(10): 1189-1197. DOI: 10.1182/blood-2017-03-775122. ［16］ Lipson EJ, Forde PM, Hammers HJ, et al. Antagonists of PD-1 and PD-L1 in cancer treatment［J］. Semin Oncol, 2015, 42(4): 587-600. DOI: 10.1053/j.seminoncol.2015.05.013. ［17］ Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents［J］. Expert Rev Respir Med, 2017, 11(10): 791-805. DOI: 10.1080/17476348.2017.1361323. ［18］ Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes［J］. Onco Targets Ther, 2016, 9: 5023-5039. DOI: 10.2147/OTT.S105862. ［19］ Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy［J］. Lancet Oncol, 2016, 17(12): e542-e551. DOI: 10.1016/S1470-2045(16)30406-5. ［20］ Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer［J］. Nat Commun, 2018, 9(1): 4664. DOI: 10.1038/s41467-018-07131-y. ［21］ Bensch F, van der Veen EL, Lubde Hooge MN, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer［J］. Nat Med, 2018, 24(12): 1852-1858. DOI: 10.1038/s41591-018-0255-8. ［22］ Chatterjee S, Lesniak WG, Miller MS, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide［J］. Biochem Biophys Res Commun, 2017, 483(1): 258-263. DOI: 10.1016/j.bbrc.2016.12.156. ［23］ De Silva RA, Kumar D, Lisok A, et al. Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer［J］. Mol Pharm, 2018, 15(9): 3946-3952. DOI: 10.1021/acs.molpharmaceut.8b00399. ［24］ Abdel-Magid AF. Inhibitors of the PD-1/PD-L1 pathway can mobilize the immune system: an innovative potential therapy for cancer and chronic infections［J］. Acs Med Chem Lett, 2015, 6(5): 489-490. DOI: 10.1021/acsmedchemlett.5b00148. ［25］ Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)［J］. Oncotarget, 2016, 7(21): 30323-30335. DOI: 10.18632/oncotarget.8730. ［26］ Guzik K, Zak KM, Grudnik P, et al. Smallmolecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1［J］. J Med Chem, 2017, 60(13): 5857-5867. DOI: 10.1021/acs.jmedchem.7b00293. ［27］ Skalniak L, Zak KM, Guzik K, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of t-cells［J］. Oncotarget, 2017, 8(42): 72167-72181. DOI: 10.18632/oncotarget.20050.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[15]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.

小分子多肽免疫抑制剂PET探针引导肿瘤免疫治疗新进展

PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价